Intercept Pharmaceuticals CEO Mark Pruzanski's 2019 pay jumps 46% to $6.6M
Intercept Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 29, 2020
Intercept Pharmaceuticals reported fiscal year 2019 executive compensation information on April 29, 2020.
In 2019, five executives at Intercept Pharmaceuticals received on average a compensation package of $3.7M, a 25% increase compared to previous year.
Average pay of disclosed executives at Intercept Pharmaceuticals
Mark Pruzanski, Chief Executive Officer, received $6.6M in total, which increased by 46% compared to 2018. 63% of Pruzanski's compensation, or $4.2M, was in stock awards. Pruzanski also received $560K in non-equity incentive plan, $1.1M in option awards, $734K in salary, as well as $7.4K in other compensation.
For fiscal year 2019, the median employee pay was $239,066 at Intercept Pharmaceuticals. Therefore, the ratio of Mark Pruzanski's pay to the median employee pay was 28 to one.
Jerome Durso, Chief Operating Officer, received a compensation package of $4.3M, which increased by 34% compared to previous year. 49% of the compensation package, or $2.1M, was in stock awards.
Ryan Sullivan, General Counsel, earned $3.1M in 2019, a 4% decrease compared to previous year.
Richard Kim, President, U.S. Commercial Strategic Marketing, received $2.4M in 2019.
Sandip Kapadia, Chief Financial Officer, earned $2.3M in 2019, a 24% increase compared to previous year.
Related executives
Mark Pruzanski
Intercept Pharmaceuticals
Chief Executive Officer
Sandip Kapadia
Intercept Pharmaceuticals
Chief Financial Officer
Jerome Durso
Intercept Pharmaceuticals
Chief Executive Officer
Ryan Sullivan
Intercept Pharmaceuticals
General Counsel
Richard Kim
Intercept Pharmaceuticals
Former President, U.S. Commercial & Strategic Marketing
You may also like
Source: SEC filing on April 29, 2020.